source
- Novartis reports Phase 3 success for MS pill remibrutinib, beats Aubagio and shows no liver safety issuesNovartis announced that its BTK inhibitor remibrutinib met primary endpoints in two Phase 3 trials in patients with relapsing multiple sclerosis. The studies showed the drug reduced annualized rel…
- Novartis and BMS pause CAR-T trials after fatal immune syndrome casesNovartis has halted several immunology and neurology studies of its CAR T candidate rapcabtagene autoleucel after three patients experienced fatal immune effector cell‑associated hemophagocytic syn…